logo
Plus   Neg
Share
Email

UK JCVI Not Recommends Novartis's Meningitis B Vaccine Bexsero For Immunization

Swiss drug maker Novartis AG (NVS), Wednesday said the UK Joint Committee on Vaccination and Immunisation or JCVI took an interim position to not recommend Bexsero vaccine for inclusion in the National Immunisation Programme, driven by evaluation based on cost-effectiveness assumptions. The company added that the JCVI does not feel that the decision is in the interest of the public.

Novartis said the JCVI made its evaluation before any pricing discussion with it and if the position is not changed, it will postpone Bexsero access.

In January 2013, the European Medicines Agency licensed Bexsero for active immunization of individuals from two months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google added bitcoin's 'B' symbol to its Keyboard on iOS devices, indicating the leading cryptocurrency's growing acceptance in the mainstream industry. The feature, however, is not added to Android keyboards. The addition of the bitcoin currency key reflects Google users' growing interest in bitcoin. According to Google Trends, 'What is Bitcoin?' was the most popular search question in 2018. Shares of Deutsche Telekom AG were losing around 2 percent in German trading after the telecom giant reported Thursday a net loss in its fourth quarter, compared to prior year's profit, despite increased revenues. Looking ahead, the company said its 2019 forecast shows undiminished growth momentum. Hormel Foods Corp. on Thursday reported a 20 percent decline in profit for the first quarter from last year, when results were aided by a benefit related to the U.S. tax reform. However, earnings per share for the quarter matched analysts' expectations, while revenues missed their estimates. Looking ahead, the branded food company reiterated its financial outlook for fiscal 2019.
Follow RTT